A Pilot Study of Risk Adapted Therapy Utilizing Upfront Brentuximab With Combination Chemotherapy in the Treatment of Children, Adolescents and Young Adults With Newly Diagnosed Hodgkin Lymphoma

Next Previous
Trial Profile

A Pilot Study of Risk Adapted Therapy Utilizing Upfront Brentuximab With Combination Chemotherapy in the Treatment of Children, Adolescents and Young Adults With Newly Diagnosed Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Doxorubicin; Rituximab; Vincristine
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 12 Dec 2017 Results (n=23) assessing safety, tolerability and response rate, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 02 Jun 2017 Results (n=19) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 23 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top